← All indications
Urologic Neoplasms
Tumors or cancer of the URINARY TRACT in either the male or the female.
Subtype terms (4)
More specific conditions that are subtypes of Urologic Neoplasms in the MeSH hierarchy.
- Kidney Neoplasms
338 drugs (164 approved, 174 experimental)
- Ureteral Neoplasms
58 drugs (45 approved, 13 experimental)
- Urethral Neoplasms
64 drugs (52 approved, 12 experimental)
- Urinary Bladder Neoplasms
519 drugs (226 approved, 293 experimental)
Drugs by status
Phase 4 trials (2)
Phase 3 trials (8)
Phase 2 trials (37)
- afatinib
- axitinib
- apatorsen
- fulvestrant
- gemcitabine
- paclitaxel
- nivolumab
- pembrolizumab
- lenvatinib
- motexafin gadolinium
- niraparib
- palbociclib
- pemetrexed
- trastuzumab
- carboplatin
- immune globulin (human)
- sacituzumab govitecan
- cetuximab
- trastuzumab emtansine
- tucatinib
- zoledronic acid
- enfortumab vedotin
- docetaxel
- varlilumab
- cisplatin
- a166
- relatlimab
- toripalimab
- tislelizumab
- cadonilimab
- +7 more
Phase 1 trials (4)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (26)
- Seattle Genetics
- Bristol-Myers Squibb
- Astellas
- Pharmacyclics
- Eli Lilly
- Exelixis
- Genentech
- Novartis
- Celldex Therapeutics
- GammaCan
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- NanOlogy, LLC
- OncoGenex Technologies
- Boehringer Ingelheim
- TesoRx Pharma, LLC
- Cornell University
- Temple University
- Stanford University
- University of Michigan
- Columbia University
- Tel Aviv University
- US Biotest
- LiPac Oncology LLC
- Pharmaceutical Research Associates, Inc. (PRA)
- BCG Oncology, PC
- Klus Pharma Inc.
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (1)